SAN DIEGO, Jan. 19 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) announced today that its Chief Science Officer, Dr. Richard H. Tullis, will give a clinical presentation of the Aethlon Hemopurifier® at the 12th International Conference on Dialysis on January 22nd. The presentation will review treatment outcomes of dialysis patients infected with Hepatitis-C (HCV), and will discuss the additional use of the Hemopurifier® in HIV and Cancer care. The conference will be held at the Marriott New Orleans in New Orleans, Louisiana. Additional information, including the speaker agenda, can be accessed online at: http://www.renalresearch.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090325/LA88762LOGO-b)

About Aethlon Medical

Aethlon Medical creates diagnostic and therapeutic device solutions for infectious disease and cancer. Our Hemopurifier® represents the first-in-class medical device to selectively adsorb viruses and immunosuppressive toxins from the bloodstream. The Hemopurifier® seeks to improve Hepatitis-C treatment outcomes and serves as a broad-spectrum treatment countermeasure against bioterror and pandemic threats. Additional information regarding Aethlon Medical can be accessed online at www.aethlonmedical.com.


    Contacts:

    RedChip Companies, Inc.
    Jon Cunningham
    1-800-733-2447, Ext. 107
    Jon@redchip.com

    Jim Joyce
    Chairman, CEO
    858.459.7800 x301
    jj@aethlonmedical.com

    Jim Frakes
    Senior VP Finance
    858.459.7800 x300
    jfrakes@aethlonmedical.com

SOURCE Aethlon Medical, Inc.